Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041.
-Seems that in Psoriasis, the higher the number of the interleukin antibody, the better! Guselkumab seems to fit this observation. It is an anti-Il-23 antibody (p19 subunit)
-It was compared with adalimumab in a phase III, double blinded trial over 48 weeks. (VOYAGE 1 trial)
-Phase II data demonstrated superior efficacy of guselkumab compared with adalimumab in moderate to severe psoriasis.
-847 patients with moderate to severe psoriasis were randomized into 3 groups: adalimumab (334), guselkumab (329), placebo (174)
-The study was done in 101 global sites.
-The study comprised an active-comparator period when guselkumab was compared with adalimumab (week 0-48) and a placebo-controlled period (weeks 0-16), after which patients taking placebo crossed over to receive guselkumab through week 48
-Guselkumab was superior to placebo by substantial margins at week 16 using 2 rigorous end points (IGA 0/1 and PASI 90). The onset of action of guselkumab was rapid, with significant response as early as week 2 compared with placebo.
-The phase III VOYAGE 1 study validates the superiority of guselkumab compared with adalimumab, including in difficult- to-treat regional disease, through 1 year of treatment.
-2 injections of guselkumab 100 mg (weeks 0 and 4) and maintenance therapy every 8 weeks effectively treats moderate to severe psoriasis.
The full article is published in the JAAD and can be accessed here: http://bit.ly/2nf4oPY
Article selected by Saurat JH, MD